MedTrace Logo

Is Venous to Arterial Conversion (v-TAC) of Blood Gas Reliable in Critical Ill Patients in the ICU?

NCT03309423 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2017-10-13

No results posted yet for this study

Summary

Objective: Arterial blood gas (ABG) is essential in the clinical assessment of potential acutely ill patients venous to arterial conversion (v-TAC), a mathematical method, has recently been developed to convert peripheral venous blood gas (VBG) values to arterialized VBG (aVBG) values. The aim of this study is to test the reliability of aVBG compared to ABG in an intensive care unit (ICU) setting.

Method: Consecutive patients admitted to the ICU with pH values \<7,35 or \>7,45 are included in this study. Paired ABG and aVBG samples are drawn from patients via arterial catheter, central venous catheter and/or peripheral venous catheter and compared.

Conditions

  • Respiratory Insufficiency
  • Metabolic Disease
  • Acidosis
  • Alkalosis
  • Sepsis
  • Abdomen, Acute

Interventions

DIAGNOSTIC_TEST

venous to arterial conversion (v-TAC)

Venous to arterial conversion (v-TAC) is a software (Obimedical, Denmark), which can convert venous blood gas values to arterial blood gas values. The principle of the method is a mathematical transformation of VBG values to arterialized values (aVBG) by simulating the transport of blood back through the tissue. To facilitate this simulation the following physiologically relevant assumptions were made: 1) The peripheral extremity was well perfused; 2) change in base excess across the tissue sampling site was approximately zero; 3) the respiratory quotient (rate of CO2 production and O2 utilisation over capillaries) could not vary outside the range 0.7 and 1.0, and 4) the haemoglobin concentration was constant from artery to vein.

Sponsors & Collaborators

  • Regionshospital Nordjylland

    collaborator OTHER_GOV

  • Aalborg University

    lead OTHER

Principal Investigators

  • Peter Leutscher · Professor, Center for Clinical Research

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-09
Primary Completion
2018-01-30
Completion
2018-03-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03309423 on ClinicalTrials.gov